Observational studyPain research & management2026
Efficacy and Safety of Desvenlafaxine for the Treatment of Persistent Idiopathic Dentoalveolar Pain: A Retrospective Observational Study.
Observational study in Pain research & management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and Safety of Desvenlafaxine for the Treatment of Persistent Idiopathic Dentoalveolar Pain: A Retrospective Observational Study.Pain research & management · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPrevious studies on serotonin and norepinephrine reuptake inhibitors (SNRIs) such as duloxetine and venlafaxine have demonstrated efficacy in treating persistent idiopathic dentoalveolar pain (PIDP). However, a third-generation SNRI with favorable tolerability remains understudied in treating PIDP. The study aims to investigate the role of desvenlafaxine in improving PIDP.
methodsClinical data for patients diagnosed with PIDP who received desvenlafaxine treatment (50-150 mg per day) from March 2024 to January 2025 were retrospectively reviewed at our hospital. Through systematic review of electronic medical records, we extracted demographic and baseline pain characteristics, along with the effectiveness and safety of desvenlafaxine during a 3-month follow-up assessed by the Numeric Rating Scale-11 (NRS-11) scores for pain and adverse effects. Binary logistic regression was used to identify predictors of response.
resultsAmong 103 patients, pain relief was achieved in 90 patients (87.4%), as evidenced by a ≥ 50% reduction in NRS-11 scores (p < 0.001), while the remaining 13 patients (12.6%) discontinued medications due to insufficient therapeutic efficacy. Binary logistic regression analysis identified shorter pain duration as an independent predictor of a favorable response to desvenlafaxine, with an odds ratio of 1.037 (95% CI = 1.016-1.058, p < 0.001). Adverse events were reported in 15 patients (14.6%), all mild and transient.
conclusionsThe administration of desvenlafaxine serves as an effective and safe therapeutic approach for patients with PIDP. Patients with a short history of PIDP are more likely to benefit from desvenlafaxine treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.